Article
Pan-transcriptome-based Candidate Therapeutic Discovery for Idiopathic Pulmonary Fibrosis
2019-10-30
Abstract excerpt
<h4>ABSTRACT</h4> <h4>BACKGROUND</h4> Although the advent of two FDA-approved therapies for idiopathic pulmonary fibrosis (IPF) has energized the field, their effects are largely suppressive than pulmonary fibrosis remission- or reversion-inducing. Hence, the pursuit for newer IPF therapeutics continues. Recent studies show that joint analysis of systems biology level information with drug-disease connectivity a...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- b339c46d-86d4-53b8-bcfc-4e55874518d0
- DOI
- 10.1101/824367
